2-(哌啶-4-基)异吲哚啉-1-酮 | 59791-82-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 中文名称: 2-(哌啶-4-基)异吲哚啉-1-酮
• 英文名称: 2-(4-piperidinyl)-2,3-dihydro-1H-isoindol-1-one
• 英文别名: 2-(piperidin-4-yl)isoindolin-1-one；2-(4-piperidinyl)-isoindolin-1-one；2-piperidin-4-yl-2,3-dihydro-isoindol-1-one；4-(1-Oxo-isoindolino)piperidin；2-piperidin-4-yl-3H-isoindol-1-one
• CAS: 59791-82-1
• 化学式: C₁₃H₁₆N₂O
• 分子量: 216.283
• InChiKey: CIIHUTUQILHWCS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933790090

反应信息

• 作为反应物：
  描述：

  2-(哌啶-4-基)异吲哚啉-1-酮 、 愈创木酚缩水甘油醚 在 N,N-二异丙基乙胺 作用下， 以 甲醇 为溶剂， 生成 2-{1-[2-Hydroxy-3-(2-methoxy-phenoxy)-propyl]-piperidin-4-yl}-2,3-dihydro-isoindol-1-one
  参考文献：
  名称：

  Discovery of (phenoxy-2-hydroxypropyl)piperidines as a novel class of voltage-gated sodium channel 1.7 inhibitors

  摘要：

  A novel class of Na(V)1.7 inhibitors has been identified by high-throughput screening followed by structure activity relationship studies. Among this series of compounds, piperidine 9o showed potent human and mouse Na(V)1.7 inhibitory activities with fair subtype selectivity over Na(V)1.5. Compound 9o successfully demonstrated analgesic efficacy in mice comparable to that of the currently used drug, mexiletine, but with an expanded central nervous system safety margin. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.09.005
• 作为产物：
  描述：

  2-[1-(phenylmethyl)-4-piperidinyl]-2,3-dihydro-1H-isoindol-1-one 在 palladium 10% on activated carbon 、 甲酸铵 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以100%的产率得到2-(哌啶-4-基)异吲哚啉-1-酮
  参考文献：
  名称：

  Discovery of a Tetrahydropyrimidin-2(1H)-one Derivative (TAK-442) as a Potent, Selective, and Orally Active Factor Xa Inhibitor

  摘要：

  Coagulation enzyme factor Xa (FXa) is a particularly promising target for the development of new anticoagulant agents. We previously reported the imidazo[1,5-c]imidazol-3-one derivative 1 as a potent and orally active FXa inhibitor. However, it was found that 1 predominantly undergoes hydrolysis upon incubation with human liver microsomes, and the human specific metabolic pathway made it difficult to predict the human pharmacokinetics. To address this issue, our synthetic efforts were focused on modification of the imidazo[1,5-c]imidazol-3-one moiety of the active metabolite 3a, derived from 1, which resulted in the discovery of the tetrahydropyrimidin-2(1H)-one derivative 5k as a highly potent and selective FXa inhibitor. Compound 5k showed no detectable amide bond cleavage in human liver microsomes, exhibited a good pharmacokinetic profile in monkeys, and had a potent antithrombotic efficacy in a rabbit model without prolongation of bleeding time. Compound 5k is currently under clinical development with the code name TAK-442.

  DOI：

  10.1021/jm901699j

文献信息

• BENZOIMIDAZOLE, TETRAHYDRO-QUINOXALINE, BENZOTRIAZOLE, DIHYDRO-IMIDAZO[4,5-c] PYRIDINONE AND DIHYDRO-ISOINDOLONE DERIVATIVES
  申请人：Bleicher Konrad

  公开号：US20080249101A1

  公开（公告）日：2008-10-09

  This invention relates to compounds of the formula wherein A, R 1 to R 3 are as defined in the specification and G is benzoimidazole, quinoxaline, benzotriazole, dihydro-imidazo[4,5-c]pyridine and dihydro-isoindolone group as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  这项发明涉及以下式的化合物 其中A，R1至R3如规范中所定义，G为苯并咪唑，喹喔啉，苯并三唑，二氢咪唑[4,5-c]吡啶和二氢异吲哚酮基团，如规范中所定义，并其药学上可接受的盐。该发明还涉及含有这种化合物的药物组合物，以及用于制备它们的方法和它们用于治疗和/或预防与调节SST受体亚型5相关的疾病。
• [EN] CYCLIC AMIDE DERIVATIVES, AND THEIR PRODUCTION AND USE AS ANTITHROMBOTIC AGENTS<br/>[FR] DÉRIVÉS D'AMIDES CYCLIQUES ET LEUR PRODUCTION ET UTILISATION COMME AGENTS ANTITHROMBOTIQUES
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2005113504A1

  公开（公告）日：2005-12-01

  The present invention provides a cyclic amide derivative useful as a drug for treating thrombosis, which is represented by the formula (I): wherein R1 represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group, W represents a bond or an optionally substituted divalent chain hydrocarbon group, a represents 0, 1, or 2, X1 represents an optionally substituted lower alkylene or an optionally substituted lower alkenylene, Y1 represents -C(O)-, -S(O)- or -S(O)2-, A represents a piperazine ring which may be further substituted or a piperidine ring which may be further substituted, X2 represents a bond or an optionally substituted lower alkylene, Y2 represents -C(O)-, -S(O)-, -S(O)2- or -C(=NR7)-, X3 represents an optionally substituted C1-4 alkylene or an optionally substituted C2-4 alkenylene, Z3 represents -N(R4)-, -O- or a bond, Z1 represents -C(R2)(R2')-, -N(R2)-, etc., and Z2 represents -C(R3)(R3')-, -N(R3)-, etc., or a salt thereof.

  本发明提供了一种环酰胺衍生物，可用作治疗血栓症的药物，其化学式为（I）：其中R1代表一个可选择取代的环烃基或一个可选择取代的杂环基，W代表一个键或一个可选择取代的双价链烃基，a代表0、1或2，X1代表一个可选择取代的较低碳烷基或一个可选择取代的较低烯烃基，Y1代表-C（O）-、-S（O）-或-S（O）2-，A代表可能进一步取代的哌嗪环或可能进一步取代的哌啶环，X2代表一个键或一个可选择取代的较低碳烷基，Y2代表-C（O）-、-S（O）-、-S（O）2-或-C（=NR7）-，X3代表一个可选择取代的C1-4烷基或一个可选择取代的C2-4烯烃基，Z3代表-N（R4）-、-O-或一个键，Z1代表-C（R2）（R2'）-、-N（R2）-等，Z2代表-C（R3）（R3'）-、-N（R3）-等，或其盐。
• N-Quinazolinylpiperidinyl-lactams
  申请人：Ciba-Geigy Corporation

  公开号：US04255429A1

  公开（公告）日：1981-03-10

  N-[1-(4-amino-2-quinazolinyl)-3- or 4-piperidinyl]-lactams, e.g., those of the formula ##STR1## and salts thereof are antihypertensive agents.

  N-[1-(4-氨基-2-喹唑啉基)-3-或4-哌啶基]-内酰胺，例如，其化学式为##STR1##及其盐是抗高血压药物。
• [EN] INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD<br/>[FR] INHIBITEURS DE LA PROTEINE MICROSOMIALE DE TRANSFERT DES TRIGLYCERIDES ET PROCEDE D'UTILISATION
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：WO1996026205A1

  公开（公告）日：1996-08-29

  (EN) Compounds are provided which inhibit microsomal triglyceride transfer protein and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases. The compounds have the structure (a, b, c or d) wherein R1 to R6, Q, and X are as defined herein.(FR) L'invention concerne des composés qui inhibent la protéine microsomiale de transfert des triglycérides et qui sont donc utiles pour abaisser le niveau des lipides du sérum et pour traiter l'athérosclérose et les maladies similaires. Les composés ont la formule (a, b, c ou d). R1 à R6, Q et X de ces formules sont définis dans la description.

  (EN) 提供了一种抑制微粒体三酰甘油转移蛋白的化合物，因此可用于降低血清脂质和治疗动脉硬化及相关疾病。这些化合物具有结构（a、b、c或d），其中R1至R6、Q和X的定义如本文所述。 (FR) 提供了一种抑制微粒体三酰甘油转移蛋白的化合物，因此可用于降低血清脂质和治疗动脉硬化及相关疾病。这些化合物具有结构（a、b、c或d），其中R1至R6、Q和X的定义如本文所述。
• Microsomal triglyceride transfer protein
  申请人：——

  公开号：US20030166590A1

  公开（公告）日：2003-09-04

  Nucleic acid sequences, particularly DNA sequences, coding for all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials. The invention also concerns polypeptide molecules comprising all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, and methods for producing these polypeptide molecules. The invention additionally concerns novel methods for preventing, stabilizing or causing regression of atherosclerosis and therapeutic agents having such activity. The invention concerns further novel methods for lowering serum liquid levels and therapeutic agents having such activity.

  核酸序列，特别是编码微粒体三酰甘油转移蛋白高分子量亚基的全部或部分的DNA序列，包含DNA序列的表达载体，包含表达载体的宿主细胞以及利用这些材料的方法。发明还涉及包含微粒体三酰甘油转移蛋白高分子量亚基的全部或部分的多肽分子，以及制备这些多肽分子的方法。此外，发明还涉及预防、稳定或导致动脉粥样硬化退化的新方法和具有此类活性的治疗剂。发明还涉及降低血清液体水平的新方法和具有此类活性的治疗剂。